![Philip Tsai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 M $ al 30/06/2026
Philip Tsai is Chief Technical Officer at Immunome, Inc. since 2024.
Dr. Tsai was Senior Vice President-Technical Development at Seagen, Inc. from 2021 to 2024.
Education includes graduate and doctorate degrees from California Institute of Technology and an undergraduate degree from the University of Illinois At Urbana–Champaign.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMUNOME, INC. 0,07 % | 23/07/2026 | 81.550 ( 0,07 % ) | 2 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMUNOME, INC. | Director Técnico/Científico/I+D | 27/06/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| SEAGEN INC. | Director Técnico/Científico/I+D | 01/04/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Immunome, Inc.
 Immunome, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which discovers, develops and commercializes antibody therapeutics | Health Technology |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
